Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Invested Capital (2020 - 2025)

Historic Invested Capital for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $31.5 million.

  • Journey Medical's Invested Capital rose 264.4% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.5 million, marking a year-over-year increase of 264.4%. This contributed to the annual value of $44.9 million for FY2024, which is 2852.57% up from last year.
  • Journey Medical's Invested Capital amounted to $31.5 million in Q3 2025, which was up 264.4% from $23.0 million recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Invested Capital ranged from a high of $56.2 million in Q1 2022 and a low of -$11.7 million during Q3 2021
  • Moreover, its 5-year median value for Invested Capital was $31.0 million (2024), whereas its average is $31.3 million.
  • As far as peak fluctuations go, Journey Medical's Invested Capital crashed by 27161.07% in 2021, and later surged by 49272.35% in 2022.
  • Over the past 5 years, Journey Medical's Invested Capital (Quarter) stood at $42.9 million in 2021, then increased by 4.41% to $44.7 million in 2022, then dropped by 21.85% to $35.0 million in 2023, then grew by 28.53% to $44.9 million in 2024, then dropped by 29.87% to $31.5 million in 2025.
  • Its Invested Capital was $31.5 million in Q3 2025, compared to $23.0 million in Q2 2025 and $23.4 million in Q1 2025.